Back to articles

BP lowering resulted in no CV benefits in HOPE-3


Use of an angiotensin-receptor blocker plus a thiazide diuretic to lower blood pressure (BP) in intermediate-risk patients without cardiovascular (CV) disease did not result in significant reductions in the risk of major CV events, according to results of the Heart Outcomes Prevention Evaluation (HOPE)-3 trial published in the New England Journal of Medicine.


Lonn EM, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–20.

Cushman WC, et al. More HOPE for prevention with statins. N Engl J Med. 2016;374:2085–7.